BioSpace News Archive

Business

Eisai, Biogen Revive Anti-Amyloid Alzheimer’s Theory with Positive Phase III Data (Updated)

The anti-amyloid approach to treating Alzheimer’s disease is seeing new life after Eisai and Biogen announced that lecanemab slowed progression of disease in a Phase III study.

September 28, 2022
·
3 min read
·
Alex Keown
Business

Genentech Teams Up with ArsenalBio in Cell Therapy Partnership (Updated)

Genentech and privately-held Arsenal Biosciences forged a multi-year collaboration to identify critical success circuits in T cell-based therapies for solid tumors.

September 28, 2022
·
3 min read
·
Alex Keown
Drug Development

Opthalmology Space Gains Clarity with Partnerships & Acquisitions by Outlook & Visus Therapeutics

A cloudy ophthalmic space got a little clearer Wednesday with the two collaborations by Visus Therapeutics and Outlook Therapeutics, now preparing for FDA approval.

September 28, 2022
·
2 min read
·
Paul Elias
Drug Development

NeuroSense PrimeC PK Data in ALS could Trigger US Enrollment

A new formulation of NeuroSense’s amyotrophic lateral sclerosis therapeutic PrimeC could pave the way for an expansion of its ongoing Phase IIb PARADIGM study into the United States.

September 28, 2022
·
3 min read
·
Alex Keown
Drug Development

World Cancer Research Day Highlights Innovation in Immuno-Oncology

In honor of World Cancer Research Day, Sept. 24, BioSpace spoke with Elevation Oncology, Janssen, Merck and Teclison to learn more about the latest innovations in immuno-oncology.

September 28, 2022
·
5 min read
·
Christie Adams and Hayley Shasteen
Business

With $68M Series A, Pheon Breaks into Competitive ADC Space

Pheon Therapeutics launched with $63 million in Series A financing and a vision of ushering in the next generation of antibody-drug conjugates.

September 28, 2022
·
2 min read
·
Tristan Manalac
Business

Money on the Move: Eagle, Elucidata, Prime Medicine and More

Funding initiatives this week saw money flow into cancer, rare liver diseases, respiratory depression, chemotherapy-related toxicities and a cutting-edge machine learning platform.

September 28, 2022
·
5 min read
·
Tristan Manalac
Drug Development

TCR2 Therapeutics’ Gavo-Cel Shows Early Promise in Solid Tumors, Ovarian Cancer

TCR2 Therapeutics announced promising Phase I data for gavo-cel in mesothelin-expression that points toward effects in multiple solid tumors, especially ovarian cancer.

September 28, 2022
·
3 min read
·
Mark Terry
Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi

As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world.

September 28, 2022
·
7 min read
Policy

Kurin, Inc. Announces Successful FDA Audit

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced the results of their recent FDA inspection.

September 28, 2022
·
1 min read